President Trump and FDA commissioner Stephen Hahn at the White House in Washington on March 19, 2020 (Yuri Gripas, Sipa via AP Images)
April 21, 2020 02:03 PM EDTUpdated April 22, 10:33 AM
R&D
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

John Carroll

Editor & Founder

Just weeks fol­low­ing the FDA’s emer­gency ap­proval of hy­drox­y­chloro­quine af­ter Pres­i­dent Trump re­peat­ed­ly ad­vo­cat­ed its use for Covid-19, new da­ta from a quick VA study …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times